721 Generic Drugs on Japan's NHI List
A total of 721 generic pharmaceutical products manufactured by 131 companies are now included on Japan's National Health Insurance Price list, the Ministry of Health and Welfare has announced. The 0.9-fold rule was used in calculations of NHI prices for 352 of the 721 products.
Since generics were first included on the NHI list, their numbers have moved from 990 in October 1987, 426 in July 1988, 985 in July 1990, and 863 in July 1992 to 721 in July 1994.
Pricing hearings conducted before the listing by the Ministry's Pharmaceutical Affairs Bureau revealed that New Drug Applications for 123 generics have been withdrawn. Of these, NDAs for six active ingredients in 19 presentations were withdrawn because of the likelihood of a patent dispute developing, in the event of their being included on the NHI listing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze